Evidence map›Paper›PMID 39063985›Full record

ReviewJournal of personalized medicine2024

Biobanks as an Indispensable Tool in the "Era" of Precision Medicine: Key Role in the Management of Complex Diseases, Such as Melanoma.

Alessandro Valenti, Italia Falcone, Fabio Valenti, Elena Ricciardi, Simona Di Martino, Maria Teresa Maccallini, Marianna Cerro, Flora Desiderio, Ludovica Miseo, Michelangelo Russillo and 1 more

Abstract readReview
In one paragraph

Review in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessandro ValentiRadiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy.ORCID 0009-0001-1327-9296
Italia FalconeSAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0003-2796-0792
Fabio ValentiUOC Oncological Translational Research, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-1098-7705
Elena RicciardiUOC Oncological Translational Research, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0001-8319-3861
Simona Di MartinoUOC Pathology Unit, Biobank IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.
Maria Teresa MaccalliniDepartment of Clinical and Molecular Medicine, Università La Sapienza di Roma, 00185 Rome, Italy.
Marianna CerroDepartment of Clinical and Molecular Medicine, Università La Sapienza di Roma, 00185 Rome, Italy.
Flora DesiderioRadiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy.
Ludovica MiseoRadiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy.ORCID 0000-0002-9038-599X
Michelangelo RussilloDivision of Medical Oncology, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.
Antonino GuerrisiRadiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, medicine has undergone profound changes, strongly entering a new phase defined as the "era of precision medicine". In this context, patient clinical management involves various scientific approaches that allow for a comprehensive pathology evaluation: from preventive processes (where applicable) to genetic and diagnostic studies. In this scenario, biobanks play an important role and, over the years, have gained increasing prestige, moving from small deposits to large collections of samples of various natures. Disease-oriented biobanks are rapidly developing as they provide useful information for the management of complex diseases, such as melanoma. Indeed, melanoma, given its highly heterogeneous characteristics, is one of the oncologic diseases with the greatest clinical and therapeutic management complexity. So, the possibility of extrapolating tissue, genetic and imaging data from dedicated biobanks could result in more selective study approaches. In this review, we specifically analyze the several biobank types to evaluate their role in technology development, patient monitoring and research of new biomarkers, especially in the melanoma context.

Indexed as

biobanksdigital biobankimaging biobankliquid biobankmelanomaprecision medicinetissue biobank

Identifiers

PMID39063985
PMCPMC11278009

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.